Bollard Group’s Celldex Therapeutics CLDX Stock Holding History

Bollard Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-19,627	Closed	-$399K	–	271
2025 Q2	$399K	Buy	+19,627	New	+$382K	0.01%	160

Other funds holding CLDX

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bollard Group's CLDX Position: Q3 2025 in Review

Bollard Group sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 19,627 shares — an estimated $399K sold.

Bollard Group first reported a position in CLDX in Q2 2025 and held it in 1 quarter. The position peaked at $399K in Q2 2025. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

Bollard Group reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
Bollard Group sold 19,627 Celldex Therapeutics shares in Q3 2025, an estimated $399K.
Bollard Group first reported a position in Celldex Therapeutics in Q2 2025 and held it in 1 quarter.
Bollard Group's Celldex Therapeutics position peaked at $399K in Q2 2025.
184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Bollard Group's 13F filing for Q3 2025, filed 14 Nov 2025.